Alzheimer disease. Irreversible AChE inhibition with metrifonate
Oberpichler-Schwenk, H.
Medizinische Monatsschrift für Pharmazeuten 21(8): 250
1998
ISSN/ISBN: 0342-9601 PMID: 9758554 Document Number: 497633
Document emailed within 1 workday
Related Documents
Unni, L.; Vicari, S.; Moriearty, P.; Schaefer, F.; Becker, R. 2000: The recovery of cerebrospinal fluid acetylcholinesterase activity in Alzheimer's disease patients after treatment with metrifonate Methods and Findings in Experimental and Clinical Pharmacology 22(1): 57-61DE Felice, F.G.; Houzel, J-Christophe.; Garcia-Abreu, Jé.; Louzada, P.Roberto.F.; Afonso, R.C.; Meirelles, M.Nazareth.L.; Lent, R.; Neto, V.Moura.; Ferreira, Sérgio.T. 2001: Inhibition of Alzheimer's disease β-amyloid aggregation, neurotoxicity, and in vivo deposition by nitrophenols: implications for Alzheimer's therapy FASEB Journal 15(7): 1297-1299
Gillen, T.E.; Gregg, K.M.; Yuan, H.; Kurth, M.C.; Krishnan, K.R. 2001: Clinical trials in Alzheimer's disease. Calculating Alzheimer's Disease Assessment Scale-cognitive subsection with the data from the consortium to establish a registry for Alzheimer's disease Psychopharmacology Bulletin 35(2): 83-96
Iwatsubo, T. 2002: The mechanism of A beta production and its inhibition as a therapeutic strategy for the prevention of Alzheimer's disease Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 120(1): 30p-33p
Zhu, J.; Huan, C.; Si, G.; Yang, H.; Yin, L.; Ren, Q.; Ren, B.; Fu, R.; Miao, M.; Ren, Z. 2015: The acetylcholinesterase (AChE) inhibition analysis of medaka (Oryzias latipes) in the exposure of three insecticides Pakistan Journal of Pharmaceutical Sciences 28(2 Suppl): 671-674
Mackell, J.A.; Ferris, S.H.; Mohs, R.; Schneider, L.; Galasko, D.; Whitehouse, P.; Schmitt, F.; Sano, M.; Thal, L.J. 1997: Multicenter evaluation of new instruments for Alzheimer's disease clinical trials: summary of results. The Alzheimer's Disease Cooperative Study Alzheimer Disease and Associated Disorders 11 Suppl. 2: S65-S69
Fukatsu, R.; Tsuzuki, K.; Hayashi, Y.; Takamaru, Y.; Sasaki, N.; Yoshida, T.; Hatakeyama, Y.; Fuji, N.; Takahata, N. 1997: Recent advances in Alzheimer's disease research--amyloid precursor protein trafficking, processing, and mutations in Alzheimer's disease linked genes Hokkaido Journal of Medical Science 72(1): 3-11
Morris, J.C.; Edland, S.; Clark, C.; Galasko, D.; Koss, E.; Mohs, R.; van Belle, G.; Fillenbaum, G.; Heyman, A. 1993: The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease Neurology 43(12): 2457-2465
Morris, J.C.; Mohs, R.C.; Rogers, H.; Fillenbaum, G.; Heyman, A. 1988: Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease Psychopharmacology Bulletin 24(4): 641-652
Miyakawa, T. 1988: Brain pathology in Alzheimer's disease. Ultrastructure of amyloid fibrils in Alzheimer's disease and Down's syndrome Nihon Rinsho. Japanese Journal of Clinical Medicine 46(7): 1471-1474
Szpak, G.M.; Lechowicz, W.; Lewandowska, E.; Bertrand, E.; Wierzba-Bobrowicz, T.; Gwiazda, E.; Schmidt-Sidor, B.; Dymecki, J. 2001: Neurones and microglia in central nervous system immune response to degenerative processes. Part 1: Alzheimer's disease and Lewy body variant of Alzheimer's disease. Quantitative study Folia Neuropathologica 39(3): 181-192
Díaz, J.Carlos.; Linnehan, J.; Pollard, H.; Arispe, N. 2006: Histidines 13 and 14 in the Abeta sequence are targets for inhibition of Alzheimer's disease Abeta ion channel and cytotoxicity Biological Research 39(3): 447-460
Decker, D.E.; Althaus, J.S.; Buxser, S.E.; VonVoigtlander, P.F.; Ruppel, P.L. 1993: Competitive irreversible inhibition of dopamine uptake by 6-hydroxydopamine Research Communications in Chemical Pathology and Pharmacology 79(2): 195-208
Minamiyama, Y.; Takemura, S.; Imaoka, S.; Funae, Y.; Tanimoto, Y.; Inoue, M. 1997: Irreversible inhibition of cytochrome P450 by nitric oxide Journal of Pharmacology and Experimental Therapeutics 283(3): 1479-1485
Bufill, E.; Blesa, R. 2006: Alzheimer's disease and brain evolution: is Alzheimer's disease an example of antagonistic pleiotropy? Revista de Neurologia 42(1): 25-33
Araki, H.; Cheng, J.T.; Taniyama, K.; Matsumoto, H. 1976: Irreversible inhibition by dibenamine of drug-induced contractions, in relation to the mobilization of Ca Kobe Journal of Medical Sciences 22(1): 35-45
Ejezie, G.C.; Ade-Serrano, M.A. 1981: Schistosoma haematobium in Ajara community of Badagry. Metrifonate trials in the treatment of the disease Tropical and Geographical Medicine 33(2): 181-184
Fărcăşel, L. 1988: Current data on the anatomy and physiopathology of Alzheimer's disease (Alzheimer-type senile dementia--ATSD) Revista Medico-Chirurgicala A Societatii de Medici Si Naturalisti Din Iasi 92(2): 289-292
Ng, H.K. 1994: Alzheimer's disease and Alzheimer-type of cerebral degenerations in Chinese Clinical and Experimental Neurology 31: 85-98
Narindrasorasak, S.; Altman, R.A.; Gonzalez-DeWhitt, P.; Greenberg, B.D.; Kisilevsky, R. 1995: An interaction between basement membrane and Alzheimer amyloid precursor proteins suggests a role in the pathogenesis of Alzheimer's disease Laboratory Investigation; A Journal of Technical Methods and Pathology 72(3): 272-282